Injection

BD Launches Simplist Generic Prefilled Injectable Products

The pharmaceutical packaging and product firm has introduced a line of prefilled injectibles designed to help improve patient safety and convenience.

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first drug to be offered in the just-launched BD Simplist™ ready-to-administer, line of prefilled generic injectables. BD Simplist prefilled injectables will be commercialized and manufactured by BD Rx Inc., a wholly-owned subsidiary of BD.  The first BD Simplist product BD Rx will launch is Diphenhydramine Hydrochloride Injection, USP, an injectable antihistamine. 

Your rating: None Average: 5 (1 vote)

BD Launches Disposable Self-injection Pen

The BD Vystra disposable self-injection pen is designed for therapies requiring frequent, low-volume injections or variable dosing.

BD Medical, a segment of BD, announced today that the BD Vystra Disposable Pen will be showcased at the 2012 Parenteral Drug Association Meeting in Las Vegas. This new self-injection pen has been designed for use with a wide range of therapies that require frequent, low-volume injections or variable dosing.

Your rating: None Average: 4 (2 votes)

BD Launches Advanced Device for Insulin Injection

The Ultra-Fine Nano 4mm pen needles include five-bevel needle tips designed to provide diabetes patients with easier insulin injection.

Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that include needle anxiety. Patients who reported injection-related pain or embarrassment also admitted they intentionally skipped insulin injections more often. A study by the American Association of Diabetes Educators (AADE) revealed that 47% of people with diabetes would be more likely to administer their injections regularly if a product were available that would ease the pain and discomfort of injections.

Your rating: None Average: 5 (1 vote)

JHP Pharmaceuticals to Produce Injectable for Cardiovascular Use

Contract manufacturer JHP Pharmaceuticals has entered into an agreement with a pharmaceutical company to produce clinical and commercial supply of an innovative injectable used in the cardiovascular setting, the company reported in a press release.

INJEX Pharma AG to Bring Needle-free Injection System to US

The company has received approval from the FDA to sell its needle-free product in America.

INJEX Pharma AG receives FDA clearance for the import and sale of the needle free injection technology INJEX 30 into the US Market

The FDA had registered INJEX Pharma GmbH, Berlin, and INJEX Pharma US, Miami, and given approval for the import and sale of INJEX 30 in the US market. The condition was the registration by the FDA for INJEX Pharma GmbH as manufacturer and exporter. This registration is now finalized.

No votes yet

Baxter Attains Approval for Hemophilia Treatment

The company has received the go-ahead for ADVATE recombinant human coagulation factor VIII for injection.

Baxter International Inc. today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA). It is estimated that more than 50,000 people in China are living with hemophilia A.

No votes yet

Hospira Recalls Morphine Sulfate Injection Syringes

The company issued the recall after customers reported detecting syringes containing more than the labeled fill volume.

Hospira Inc. is initiating a voluntary user level recall of one lot of Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1258-30, due to a customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume.

Opioid pain medications such as morphine have life-threatening consequences if overdosed.  Those consequences can include respiratory depression (slowed breathing or suspension of breathing), and low blood pressure.

No votes yet
Syndicate content